Apogee Therapeutics, Inc.
APGE
$38.40
$2.055.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.51% | 6.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.96% | -16.85% | |||
| Operating Income | -15.96% | 16.85% | |||
| Income Before Tax | -19.49% | 17.77% | |||
| Income Tax Expenses | -13.25% | 361.11% | |||
| Earnings from Continuing Operations | -19.44% | 17.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.44% | 17.67% | |||
| EBIT | -15.96% | 16.85% | |||
| EBITDA | -15.71% | 17.04% | |||
| EPS Basic | -18.96% | 19.01% | |||
| Normalized Basic EPS | -19.01% | 19.11% | |||
| EPS Diluted | -18.96% | 19.01% | |||
| Normalized Diluted EPS | -19.01% | 19.11% | |||
| Average Basic Shares Outstanding | 0.40% | 1.65% | |||
| Average Diluted Shares Outstanding | 0.40% | 1.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||